滋肾活血方治疗肾虚血瘀型卵巢早衰的临床研究
|
摘要
目的探究和分析滋肾活血方加减治疗肾虚血瘀型卵巢早衰的疗效。方法选取2016年5月—2018年4月接收治疗的76例肾虚兼血瘀型卵巢早衰患者,随机分为试验组和对照组各38例,对照组应用激素替代疗法(结合雌激素片+醋酸甲羟孕酮片)治疗,试验组在对照组的基础上服用滋肾活血方进行治疗,治疗3个疗程之后,对比观察2组临床疗效,治疗前后血清中黄体生成素(LH)、抑制素(INH-B)、雌二醇(E2)、卵泡刺激素(FSH)水平的变化,治疗后症状改善评分变化情况。结果试验组治疗的总有效率为86.84%,明显高于对照组总有效率65.79%,具有显著的统计学差异(P<0.05)。2组患者在治疗后血清中LH、FSH水平都呈下降趋势,但试验组水平要低于对照组(P<0.05),血清中E2、INH-B都呈上升趋势,但试验组水平要高于对照组(P<0.05)。试验组在治疗后症状改善评分要低于对照组(P<0.05)。结论滋肾活血方联合激素治疗肾虚兼血瘀型卵巢早衰效果显著,能有效调节性激素水平,安全性高,改善了临床症状,值得临床推广应用。
Objective To explore and analyze the clinical research of modified kidney-nourishing and blood-activating prescription in treating premature ovarian failure of kidney deficiency and blood stasis type. Methods 76 patients with kidney deficiency and blood stasis type premature ovarian failure in our hospital from May 2016 to April 2018 were randomly divided into the experimental group and the control group, with 38 cases in each group. The control group was treated with hormone replacement therapy(Conjugated Estrogens tablets + Medroxyprogesterone Acetate tablets), and the experimental group used modified kidney-nourishing and bloodactivating prescription on the basis of the control group. After three courses of treatment, the clinical curative effect of two groups was observed and the changes of serum levels of luteinizing hormone(LH), inhibin(INH-B), estradiol(E2) and follicle stimulating hormone(FSH), and the improvement on symptoms were observed before and after treatment. Results The total effective rate of the experimental group was 86.84%, which was significantly higher than that of the control group(65.79%). There was a significant statistical difference(P < 0.05). The level of serum LH and FSH decreased in the two groups after treatment, but the level of the experimental group was lower than that of the control group(P< 0.05). The serum levels of E2 and INH-B were all rising, but the level of the experimental group was higher than that of the control group(P < 0.05). The symptom improvement score of the experimental group was lower than that of the control group after treatment(P < 0.05). Conclusion The effect of modified kidney-nourishing and blood-activating prescription combined with hormone in the treatment of premature ovarian failure of kidney deficiency and blood stasis type is significant. It can effectively regulate the level of sex hormone, high safety and improve the clinical symptoms. It is worthy of clinical application.
Objective To explore and analyze the clinical research of modified kidney-nourishing and blood-activating prescription in treating premature ovarian failure of kidney deficiency and blood stasis type. Methods 76 patients with kidney deficiency and blood stasis type premature ovarian failure in our hospital from May 2016 to April 2018 were randomly divided into the experimental group and the control group, with 38 cases in each group. The control group was treated with hormone replacement therapy(Conjugated Estrogens tablets + Medroxyprogesterone Acetate tablets), and the experimental group used modified kidney-nourishing and bloodactivating prescription on the basis of the control group. After three courses of treatment, the clinical curative effect of two groups was observed and the changes of serum levels of luteinizing hormone(LH), inhibin(INH-B), estradiol(E2) and follicle stimulating hormone(FSH), and the improvement on symptoms were observed before and after treatment. Results The total effective rate of the experimental group was 86.84%, which was significantly higher than that of the control group(65.79%). There was a significant statistical difference(P < 0.05). The level of serum LH and FSH decreased in the two groups after treatment, but the level of the experimental group was lower than that of the control group(P< 0.05). The serum levels of E2 and INH-B were all rising, but the level of the experimental group was higher than that of the control group(P < 0.05). The symptom improvement score of the experimental group was lower than that of the control group after treatment(P < 0.05). Conclusion The effect of modified kidney-nourishing and blood-activating prescription combined with hormone in the treatment of premature ovarian failure of kidney deficiency and blood stasis type is significant. It can effectively regulate the level of sex hormone, high safety and improve the clinical symptoms. It is worthy of clinical application.
引文
[1]谢江燕,赵俪梅,东亚君,等.卵巢早衰的免疫学研究进展[J].实用妇产科杂志,2013,29(4):259-262.
[2]覃春容,姚吉龙,朱文杰,等.特发性卵巢早衰发病相关因素分析[J].实用妇产科杂志,2013,29(2):133-136.
[3]金志春,黄晓桃,杨雅琴,等.补肾活血方联合雌孕激素治疗卵巢早衰的临床研究[J].中国中西医结合杂志,2013,33(5):586-589.
[4]中华人民共和国卫生部.中药新药临床研究指导原则(第一辑)[S].北京:中华人民共和国卫生部,1993:241-245,262.
[5]王艳梅.中西医结合治疗卵巢早衰45例疗效观察[J].河北中医,2015,37(3):379-381.
[6]阮凡,石吟,李丽洁.中药补肾养血方联合激素替代法对卵巢早衰患者性激素水平及症状评分的影响[J].中国生化药物杂志,2016,36(12):118-120,123.
[7]张文红,赵彦鹏,李果,等.滋肾益经活血汤治疗卵巢早衰患者50例临床观察[J].世界中西医结合杂志,2012,7(8):670-671,705.
[8]徐碧红,李茂清,骆宇戟.补肾调经方配合激素替代疗法治疗卵巢早衰患者的临床观察[J].中国中西医结合杂志,2013,33(10):1332-1335.
[2]覃春容,姚吉龙,朱文杰,等.特发性卵巢早衰发病相关因素分析[J].实用妇产科杂志,2013,29(2):133-136.
[3]金志春,黄晓桃,杨雅琴,等.补肾活血方联合雌孕激素治疗卵巢早衰的临床研究[J].中国中西医结合杂志,2013,33(5):586-589.
[4]中华人民共和国卫生部.中药新药临床研究指导原则(第一辑)[S].北京:中华人民共和国卫生部,1993:241-245,262.
[5]王艳梅.中西医结合治疗卵巢早衰45例疗效观察[J].河北中医,2015,37(3):379-381.
[6]阮凡,石吟,李丽洁.中药补肾养血方联合激素替代法对卵巢早衰患者性激素水平及症状评分的影响[J].中国生化药物杂志,2016,36(12):118-120,123.
[7]张文红,赵彦鹏,李果,等.滋肾益经活血汤治疗卵巢早衰患者50例临床观察[J].世界中西医结合杂志,2012,7(8):670-671,705.
[8]徐碧红,李茂清,骆宇戟.补肾调经方配合激素替代疗法治疗卵巢早衰患者的临床观察[J].中国中西医结合杂志,2013,33(10):1332-1335.